ClinicalTrials.gg
RecruitingNCT07402031Updated May 14, 2026

Predicting Weight Loss After Pharmacological or Surgical Treatment in Patients With Obesity

An observational study in Obesity & Overweight, sponsored by Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Université Catholique de Louvain · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Obesity with a site in Belgium — 40 open to participants now, 56 under way, 22 of them phase 3. Obesity · Belgium.

Planned enrollment
19th of 35
100 · median 150
Started
2026
with 15 others
Observational
35 of 133
16 open now
Primary completion
2032-06
later than 52 of 55 live
Registered
120th of 133
by date

Among the 133 studies in Obesity with a site in Belgium, this one is the 19th largest by planned enrollment of the 35 observational ones that give a count, is one of 16 that started in 2026, is one of 35 observational ones, reaches primary completion later than 52 of the 55 other live ones, and was the 120th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

40 of the 133 studies in Obesity with a site in Belgium are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Obesity with a site in Belgium, or all of them as a file.
02

Study summary

As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.

03

Conditions studied

  • Obesity & Overweight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants initiating an anti-obesity medication or candidates for bariatric surgery once its indication has been validated by a multidisciplinary committee, following medical, nutritional and psychological evaluations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment.
  • Good physical and mental health, enabling .
  • French speaker

Exclusion criteria

Exclusion criteria:

  • Legal protection
  • Pregnancy or breastfeeding
  • History of bariatric surgery (except gastric banding, provided it was removed more than five years ago).
  • Acute or progressive chronic disease
  • Alcohol consumption of more than 20 g/day
  • Inflammatory bowel disease;
  • Digestive autonomic diabetic neuropathy.
  • Consumption of dietary supplements (stanols, probiotics, prebiotics or omega-3).
  • Following a vegan or gluten-free diet or being lactose intolerant.
  • Fibre consumption >30 g/day
  • Recent change in antidiabetic medication within the past 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • ProcedurePharmacological or surgical treament of obesity

    Longitudinal follow-up of participants who initiate an anti-obesity medication or whose application for bariatric surgery was accepted. It will combine anthropometric, clinical, neuropsychological and biological measurements taken at various timepoints. Participants will be asked to complete a set of online questionnaires and data will be recorded anonymously. Biological samples will be collected at various time points.

06

What researchers measure

Primary outcomes

  1. Correlation between weight loss after treatment and clinical, neuropsychological and biological parameters.

    The percentage of excessive weight loss after treatment will be correlated with * Clinical parameters (Binge Eating Scale and modified Yale Food Addiction Scale 2.0) * Neuropsychological parameter (Barratt Impulsivness Scale and Trail Making Test) * Biological parameters

    Time frame: Throughout the entire study, aproximately during 5 years

Secondary outcomes

  1. Binge Eating Disorder.

    Evaluation of eating disorders using the Binge Eating Scale (BES).

    Time frame: Throughout the entire study, aproximately during 5 years

  2. Food Addiction.

    Evaluation of food addiction will be performed using modified Yale Food Addiction Scale 2.0.

    Time frame: Throughout the entire study, aproximately during 5 years

  3. Eating attitudes

    Eating patterns and habits will be screened using the Eating Attitude Test 26

    Time frame: Throughout the entire study, aproximately during 5 years

  4. Cognitive flexibility.

    Neuropsychological evaluation of cognitive flexibility will be performed with the Trail Making Test

    Time frame: Throughout the entire study, aproximately during 5 years

  5. Impulsivity.

    Impulsivity will be assessed using the Barrat Impulsiveness Scale (BIS)

    Time frame: Throughout the entire study, aproximately during 5 years

  6. Self-reported quality of life.

    Self-reported quality of life will be assessed using the QOLOD (Quality of Life, Obesity and Dietetics)

    Time frame: Throughout the entire study, aproximately during 5 years

  7. Obesity.

    Weight will be measured at each timepoint

    Time frame: Throughout the entire study, aproximately during 5 years

  8. Physical activity.

    Weekly physical activity will be reported with the Godin Leisure Time Exercise Questionnaire (GLTEQ)

    Time frame: Throughout the entire study, aproximately during 5 years

  9. Food intake.

    Eating habits will be recorded with a Food Frequency Questionnaire (FFQ)

    Time frame: Throughout the entire study, aproximately during 5 years

  10. Blood samples

    Blood samples will be collected and processed for metabolomic analyses.

    Time frame: Throughout the entire study, aproximately during 5 years

  11. Fecal sample

    Feces samples will be collected and processed to evaluation gut-microbiota composition

    Time frame: Throughout the entire study, aproximately during 5 years

Other outcomes

  1. Sociodemographic data

    Number of children and marital status will be recorded

    Time frame: Once at inclusion

  2. Medical history

    Information concerning medical comorbidities will be collected from the patient medical record.

    Time frame: Once at inclusion

  3. Childhood Trauma.

    Assessment of adverse life events and trauma will used the Childhood Trauma Questionnaire - short form.

    Time frame: Once at inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jun 2032, 73 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 73 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Feb 11, 2026
StartActual
May 5, 2026
Primary completionEst.
Jun 2032
CompletionEst.
Jan 2036
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07402031
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
May 5, 2026
Primary completion
Jun 2032 (estimated)
Completion
Jan 2036 (estimated)
Last update
May 14, 2026

Study contacts

Pr Amandine Everard, Professor
Contact
amandine.everard@uclouvain.be
+ 32 (0)2 436 22 10 ext. +32
Yannick Deswysen, Doctor
Contact
yannick.deswysen@saintluc.uclouvain.be
+ 32 2 764 22 13 ext. +32
Amandine Everard, Professor
study director · Université Catholique de Louvain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion